Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
positive publishing date : 2021 - 05 - 24 save search
Aptorum Group Announces Positive Interim Phase I Clinical Trial Progress for ALS-4 Targeting Staphylococcus aureus and Positive Pre-IND Progress for SACT-1 Targeting Neuroblastoma
Published: 2021-05-24 (Crawled : 13:00) - biospace.com/
APM | $5.69 3.45% 3.34% 17K
|
Health Technology
|
| O: 9.75%
H: 35.53%
C: 7.2%
positive trial als staphylococcus aureus
BrainsWay Announces First of its Kind Positive Coverage Policy by Centene for the Treatment of OCD Utilizing Deep TMS™
Published: 2021-05-24 (Crawled : 12:15) - globenewswire.com
CNC | $76.19 0.46% 0.0% 2.8M
|
Health Services
|
| O: 0.31%
H: 0.58%
C: -0.05%
BWAY | $5.03 1.93% 1.89% 26K
|
Health Technology
|
| O: 12.93%
H: 2.5%
C: -2.11%
treatment positive
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy as First-Line Treatment for Certain Patients With Esophageal Cancer or HER2-Negative Gastroesophageal Junction (GEJ) Adenocarcinoma
Published: 2021-05-24 (Crawled : 12:00) - biospace.com/
MRK | $127.0 0.1% -1.21% 7.1M
|
Health Technology
|
| O: 0.44%
H: 0.15%
C: -0.63%
treatment positive therapy cancer chmp her2+ keytruda her2- her2
Iridium Makes Strategic Investment in DDK Positioning, Provider of Enhanced GNSS Accuracy Solutions
Published: 2021-05-24 (Crawled : 12:00) - prnewswire.com
IRDM | News | $29.29 1.91% 1.88% 1.9M
|
Communications
|
| O: 0.87%
H: 0.91%
C: 0.08%
positive
Positive Clinical Data About Axcella’s AXA1665 Candidate for Overt Hepatic Encephalopathy Highlighted in Oral Presentation at DDW 2021
Published: 2021-05-24 (Crawled : 12:00) - biospace.com/
AXLA | $4.58 -56.33% 42K
|
Health Technology
|
| O: 7.19%
H: 3.88%
C: -12.01%
presentation positive hepatitis
4D pharma Presents Additional Positive Results of Phase II Study of Blautix® for the Treatment of Irritable Bowel Syndrome
Published: 2021-05-24 (Crawled : 06:00) - 4dpharmaplc.com
LBPS | $1.65 -0.61%
|
Manufacturing
| Email alert
Add to watchlist
positive treatment positive results results syndros
Libtayo® (cemiplimab) Receives Positive CHMP Opinion for the Treatment in Europe of Two Advanced Cancers
Published: 2021-05-24 (Crawled : 06:00) - prnewswire.com
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.02%
H: 0.3%
C: -0.3%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: 0.6%
H: 0.0%
C: -1.82%
treatment europe positive cancer chmp
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.